These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11137835)

  • 1. Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension.
    Schussheim AE; Diamond JA; Phillips RA
    Am J Cardiol; 2001 Jan; 87(1):61-5. PubMed ID: 11137835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy.
    Mayet J; Ariff B; Wasan B; Chapman N; Shahi M; Poulter NR; Sever PS; Foale RA; Thom SA
    Hypertension; 2000 Nov; 36(5):755-9. PubMed ID: 11082139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of hypotensive drugs on left ventricular mass and diastolic function].
    Spring A; Haczyński J; Jołda-Mydłowska B; Witkowska M
    Pol Arch Med Wewn; 1995 Jul; 94(1):47-58. PubMed ID: 8524699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of regression of left ventricular hypertrophy from systemic hypertension on systolic function assessed by midwall shortening (HOT echocardiographic study).
    Zabalgoitia M; Rahman SN; Haley WE; Yarows S; Krause L; Anderson LC; Oraby MA; Amarena J
    Am J Cardiol; 2001 Sep; 88(5):521-5. PubMed ID: 11524061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in midwall systolic performance and cardiac hypertrophy reduction in hypertensive patients.
    Muiesan ML; Salvetti M; Monteduro C; Rizzoni D; Corbellini C; Castellano M; Porteri E; Agabiti-Rosei E
    J Hypertens; 2000 Nov; 18(11):1651-6. PubMed ID: 11081779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
    Kucukler N; Kurt IH; Topaloglu C; Gurbuz S; Yalcin F
    J Cardiovasc Med (Hagerstown); 2012 Mar; 13(3):181-6. PubMed ID: 22306782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of combination therapy on regression of left ventricular hypertrophy in cases with hypertension.
    Boydak B; Nalbantgil S; Yilmaz H; Zoghi M; Ozerkan F; Nalbantgil I; Onder R
    Saudi Med J; 2004 Dec; 25(12):1975-8. PubMed ID: 15711679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study.
    Gerdts E; Okin PM; Omvik P; Wachtell K; Dahlöf B; Hildebrandt P; Nieminen MS; Devereux RB
    Nutr Metab Cardiovasc Dis; 2009 Jun; 19(5):306-12. PubMed ID: 19303268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry.
    Perlini S; Muiesan ML; Cuspidi C; Sampieri L; Trimarco B; Aurigemma GP; Agabiti-Rosei E; Mancia G
    Circulation; 2001 Feb; 103(5):678-83. PubMed ID: 11156879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left Ventricular Hypertrophy in Hypertensive Athletes can be Reduced by Antihypertensive Medication Despite Continuing Intense Aerobic Exercise.
    Ketelhut S; Franz IW; Ketelhut RG
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):385-390. PubMed ID: 30341642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
    Wachtell K; Palmieri V; Olsen MH; Gerdts E; Papademetriou V; Nieminen MS; Smith G; Dahlöf B; Aurigemma GP; Devereux RB
    Circulation; 2002 Jul; 106(2):227-32. PubMed ID: 12105163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of left ventricular hypertrophy in hypertensive patients with a combination of verapamil and captopril--a multicenter study.
    Magometschnigg D; Brandt D; Hofmann R; Sihorsch K; Stoschitzky K; Zangeneh M; Zenker G
    Int J Clin Pharmacol Ther; 1997 Sep; 35(9):389-96. PubMed ID: 9314093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study.
    Narayan P; Papademetriou V; Wachtell K; Gerdts E; Boman K; Nieminen MS; de Simone G; Dahlöf B; Fyhrquist F; Hoieggen A; Devereux RB
    Hypertension; 2006 May; 47(5):868-73. PubMed ID: 16567586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left ventricular diastolic dyssynchrony in patients with treatment-naive hypertension and the effects of antihypertensive therapy.
    Kwon BJ; Lee SH; Park CS; Kim DB; Park HJ; Jang SW; Ihm SH; Youn HJ; Seung KB; Kim HY
    J Hypertens; 2015 Feb; 33(2):354-65. PubMed ID: 25333681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is echo-determined left ventricular geometry associated with ventricular filling and midwall shortening in hypertensive ventricular hypertrophy?
    Palmiero P; Maiello M; Nanda NC
    Echocardiography; 2008 Jan; 25(1):20-6. PubMed ID: 18186776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
    Cohen A; Bregman B; Agabiti Rosei E; Williams B; Dubourg O; Clairefond P; Brudi P; Gosse P; Guéret P
    J Hum Hypertens; 1998 Jul; 12(7):479-83. PubMed ID: 9702935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study.
    Rakić D; Rumboldt Z; Bagatin J; Polić S
    Croat Med J; 2002 Dec; 43(6):672-9. PubMed ID: 12476475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.